Article Text

Download PDFPDF
What do beta-lactams add to vancomycin or daptomycin in the treatment of patients with methicillin-resistant Staphylococcus aureus bacteraemia? A review
  1. Laura García Aragonés,
  2. José Javier Blanch Sancho,
  3. Juan Carlos Segura Luque,
  4. Fernando Mateos Rodriguez,
  5. Elisa Martínez Alfaro,
  6. Julián Solís García del Pozo
  1. Albacete University Hospital Complex, Albacete, Castilla-La Mancha, Spain
  1. Correspondence to Dr Julián Solís García del Pozo, Albacete University Hospital Complex, Albacete 02006, Spain; julianeloysolis{at}gmail.com

Abstract

Several studies have documented the synergy between vancomycin/daptomycin and various beta-lactams, and clinical studies have studied this combination therapy in humans. We review the published literature on this topic to know the utility of the combined treatment with beta-lactams in treating bacteraemia methicillin-resistant Staphylococcus aureus (MRSA) infections. Fifteen observational studies, three randomised clinical trials and three systematics reviews are analysed in this article. Observational studies used ceftaroline, cefazolin, piperacillin/tazobactam or cefepime among the beta-lactams. Clinical trials used cloxacillin or flucloxacillin as the most used beta-lactam in two trials and ceftaroline in one. Three systematic reviews are published. One of them only includes studies with vancomycin and included six studies. The other two systematic reviews include patients with daptomycin or vancomycin and included 15 and 9 studies, respectively. Adding a beta-lactam to vancomycin or daptomycin may help shorten bacteraemia and avoid recurrences in patients with MRSA bacteraemia. There is no evidence that combined therapy improves mortality. Nephrotoxicity in clinical trials precludes the use of combination therapy mainly with cloxacillin or flucloxacillin, but systematic reviews have not found a significant difference in this point in observational studies with other beta-lactams. The role of other beta-lactams such as ceftaroline should be thoroughly studied in these patients.

Statistics from Altmetric.com

Footnotes

  • Contributors The paper was initiated and coordinated by the corresponding (JSGP) and the first author (LGA). JJBS contributed to the initial conception of the work. LGA and JSGdP wrote the manuscript. JJBS, JCSL, FMR and EMA contributed to the manuscript helping the first and corresponding author, providing bibliography and reviewing the manuscript.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient consent for publication Not required.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.